Introduction
Myelodysplastic syndrome (MDS) is a well-described complication of cytotoxic chemotherapy when given as treatment for lymphoid malignancies. [1] [2] [3] [4] It may occur after non-transplant cytotoxic therapy or after autologous hematopoietic cell transplantation (HCT). In fact, published data suggest that MDS after autologous HCT is related to pre-HCT therapy. 1, 5 Occasionally, MDS is diagnosed in previously untreated patients simultaneously with lymphoma. [6] [7] [8] [9] Allogeneic HCT offers potentially curative treatment for both disease entities, including disease in those patients who have failed to respond to non-transplant therapy. 10, 11 We and others have previously reported our experience with allogeneic HCT for patients with therapy-related MDS, following treatment for lymphoid malignancies, but without evidence of the primary disease at the time of HCT. 12, 13 In the present study, we identified patients who underwent allogeneic HCT for MDS, but concurrently had an active lymphoid malignancy and were diagnosed either simultaneously with MDS or preceding the diagnosis of MDS. Patients with antecedent lymphoid malignancies had received cytotoxic therapy. Patients included in this report were treated over an extended time interval during which treatment strategies have evolved. However, the data should draw attention to those patient populations for whom more effective therapeutic options must be developed.
Patients and methods
From a database of 1100 patients with MDS or related disorders who underwent allogeneic HCT at the Fred Hutchinson Cancer Research Center (FHCRC) from 1990 to 2009, 21 patients were identified who, in addition to MDS, had an active lymphoid malignancy present at the time of HCT. The study was approved by the Institutional Review Board of the FHCRC.
Patients without previous cytotoxic therapy
A total of four patients had never received cytotoxic chemotherapy, and MDS appeared to represent a de novo disorder (Cohort A, Table 1 ). These patients ranged in age from 41 to 65 (median 57) years at the time of HCT. The MDS subtypes according to the WHO classification are shown in Table 1 . The median percentage of marrow myeloblasts was 9.3%. Two of the four patients had goodrisk cytogenetics (normal karyotype) and two had an intermediate-risk karyotype according to the International Prognostic Scoring System (IPSS) criteria. 14 The IPSS scores ranged from 0.5 to 2.0, with a median score of 0.5. All four patients were diagnosed concurrently to also have CLL/small lymphocytic lymphoma (SLL), stage 0. All the patients received high-dose conditioning followed by hematopoietic stem cell infusion from HLA-matched related or unrelated donors. Further details are provided in Table 1 .
Patients who had previously received cytotoxic therapy A total of 17 patients, 29-71 (median 50.4) years of age, had previously received cytotoxic therapy (Cohort B, Table 1 ). Among these, seven had undergone high-dose chemotherapy followed by autologous HCT. Details are provided in Table 1 . In addition to MDS, five patients had concurrent CLL, while the remainder had other lymphoid malignancies, including follicular lymphoma, diffuse large B cell (DLBCL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) or multiple myeloma. One patient had T-cell ALL. In all, 5 patients had good-risk, 1 patient had intermediate-risk and 11 patients had high-risk/complex karyotypes. The median marrow myeloblast percentage was 11.3%. In 14 of 17 patients there was marrow involvement by the lymphoid malignancy. Supradiaphragmatic or infradiaphragmatic lymph node enlargement was present in both patients with HL, in five of seven patients with NHL and in the patient with HL and DLBCL. CLL was Rai stage 0 in one patient, stage I in one patient, and stage IV in the remaining three patients. The patient with myeloma was staged as Durie-Salmon stage I. A total of 10 patients were conditioned with highdose regimens, whereas 5 patients received low-intensity conditioning regimens. The remaining two patients were transplanted with marrow from haploidentical children, following conditioning with a modified reduced-intensity regimen (see Table 1 ).
Source of stem cells
The stem cell source was BM in one of four patients with primary MDS, whereas three patients were given G-CSFmobilized PBSCs. In patients with secondary MDS, nine received marrow and eight received G-CSF-mobilized PBSC as a source of stem cells. GVHD prophylaxis and therapy GVHD prophylaxis consisted of cyclosporine (CSP) 16 and MTX 17 in 12 patients, tacrolimus 18 and MTX in 4, CSP and mycophenolate mofetil (MMF) in 4, tacrolimus and MMF in 1, and CSP alone in 1 patient. The diagnosis of acute and chronic GVHD was made by established criteria. 19, 20 Assessment of results Engraftment, GVHD and relapse were assessed as previously described. 15, 21, 22 Patients who died with evidence of persistent or recurrent disease-MDS or lymphoid malignancy-were considered to have died from MDS or lymphoid malignancy, regardless of the immediate cause of death. All other deaths were considered to be related to non-relapse causes.
Data were analyzed as of 19 July 2010.
Results

Engraftment
All patients with primary MDS ( Table 2) achieved neutrophil engraftment (40.5 Â 10 9 /L for 3 days) by day 28. Among patients with secondary MDS, 15 patients achieved neutrophil engraftment; two patients died early (at 14 and 7 days, respectively) from non-relapse causes and thus were not evaluable for engraftment ( Table 2 ). All remaining patients had achieved engraftment by day 44.
GVHD
Among patients with primary MDS (Cohort A), two (50%) developed acute GVHD grades I-II, and two developed chronic GVHD. Among patients with secondary MDS (Cohort B), 13 of 15 evaluable patients (87%) developed acute GVHD, grades I-II in 10 and grades III-IV in 3 patients, and 7 of 13 patients at risk developed chronic GVHD ( Table 2) .
Relapse
Among four patients with primary MDS, 2 (50%) showed persistence of CLL and eventually relapsed with MDS. Among 17 patients with secondary MDS, one (patient 7) died too early to assess for clearance of the disease. Among the remaining 16 patients, the lymphoid malignancy persisted in three (patients 9, 10 and 15), which was not unexpected as clonal cells in these disorders often clear only gradually. 23 However, two patients (patients 9 and 15) died with progression of their lymphoid malignancy and associated complications, whereas one patient (patient 10) died with relapsed MDS. In the remaining 13 patients, both myeloid and lymphoid malignancies cleared after HCT before relapse which was documented in four of them (Table 2) .
Survival
The median follow-up for all patients was 6.2 months. At the time of analysis, 2 of 4 patients with primary MDS were alive without evidence of disease at 14 and 4 years after HCT, respectively. Two patients died with relapse of MDS and CLL at 5.1 and 46 months, respectively ( Table 2) . Among patients with secondary MDS, 2 of 17 patients were alive at the time of analysis, in apparent remission of MDS and lymphoid malignancy, at 11.9 and 15 years after HCT, respectively. Nine patients died from non-relapse causes and six from disease relapse. For all 17 patients the median relapse-free survival was 4.3 months, and the median OS was 6.2 months ( Table 2 ).
Discussion
We identified 21 patients who underwent allogeneic HCT for MDS in the setting of a concurrent lymphoid malignancy. In four patients the concurrent diagnoses of MDS and lymphoid malignancy were established simultaneously before any therapy. A total of 17 patients received a diagnosis of MDS following a preceding diagnosis and therapy for their lymphoid malignancy, and therefore were considered to have secondary MDS. Our findings are consistent with previous studies, which have shown the presence of various lymphoid malignancies in association with MDS. 6 Also consistent with previous reports is the fact that the most frequent lymphoid malignancy among patients with MDS was CLL. 6 The relationship between primary MDS and lymphoid malignancies is unclear. Although MDS is considered a myeloid disorder, it can rarely, transform to acute lymphocytic leukemia. 24 Furthermore, in an experimental xenotransplantation model of MDS, identical clonal abnormalities have been demonstrated in lymphoid and myeloid precursors. 25 Consistent with such a model, MDSassociated cytogenetic abnormalities have been observed in circulating lymphoid cells in MDS patients. 26 However, in the majority of reports of lymphoid malignancies associated with MDS, there has been no evidence of a common cell of origin. [7] [8] [9] 27 As both disorders occur with increasing frequency at older age, the simultaneous diagnosis of two malignancies may be a coincidence. By the age of 60 years about 3% of the population express small B-cell clones, and progression to CLL has been observed. 28, 29 It is conceivable that immunological abnormalities associated with MDS may facilitate such a progression. 30, 31 The development of MDS, following treatment for other malignancies, including lymphoid neoplasms is well documented. 1, 2, 32 As observed here, those patients typically show higher-risk features, in particular high-risk cytogenetics, than do patients with de novo MDS. 1 The 17 patients considered here had received cytotoxic chemotherapy, but showed persistent or recurrent evidence of their lymphoid malignancies at the time of HCT for MDS. Thus, the transplant was undertaken in an attempt to eradicate both MDS and lymphoid malignancy. Treatment failures among patients with de novo MDS were related to relapse of either MDS or CLL. Among patients with secondary MDS, relapses of either myeloid or lymphoid malignancy (or both) occurred in seven patients, but mortality was primarily due to non-relapse causes. The most prominent causes of death were related to infections. As all these patients had previously received cytotoxic therapy, often with multiple agents and for multiple cycles, increased nonrelapse mortality was expected.
Notably, in the cohort with secondary MDS patients experienced a relapse of one, but not the other disease, suggesting that a given conditioning regimen was effective in eradicating myeloid or lymphoid malignant cells, but not both. However, these data should be interpreted with great caution as the tumor burden of the two malignancies may have differed significantly. Also, the follow-up for some of these patients was short.
Of the 5 patients conditioned with low-intensity conditioning regimens, 3 died from non-relapse causes, as did 6 of 10 patients conditioned with higher-intensity regimens. Both patients who underwent haploidentical transplants died from relapse. Nevertheless, two patients with de novo MDS and CLL (one transplanted from a related and one from an unrelated donor) are surviving in remission from both diseases, as are two patients with secondary MDS, whose original lymphoid malignancies were HL and NHL, respectively.
Altogether, these data suggest that patients with MDS and concurrent lymphoid malignancies, diagnosed simultaneously or metachronously, should not a priori be excluded from consideration of transplantation. However, both relapse and non-relapse mortality were high, and better tolerable regimens must be developed, particularly for patients with secondary MDS. As therapy given for the initial diagnosis of a lymphoid malignancy may vary greatly, 'customdesigned' conditioning regimens should aim at minimizing toxicity, which may develop on the background of previously administered therapy. Conceivably, post-HCT adjuvant therapy, for example, with hypomethylating agents, 33 directed at MDS or with rituximab directed at certain lymphoid malignancies, might reduce the relapse risk without adding to transplant-related toxicity.
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